Keros Therapeutics (KROS) Other financing activities (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Other financing activities came in at $115000.0 in Q4 2025, down 95.3% YoY from $2.4 million in Q4 2024, and up 5650.0% on a QoQ basis from $2000.0 in Q3 2025.
Keros Therapeutics (KROS) Other financing activities (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Other financing activities data on file, last reported at $115000.0 in Q4 2025.
- Quarterly Other financing activities fell 95.3% year-over-year to $115000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $138000.0 (down 98.86% YoY) and the FY2025 annual result came in at $138000.0, down 98.86% from the prior year.
- Other financing activities rose to $115000.0 in Q4 2025, from $2000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $5.7 million in Q1 2024 to a low of $2000.0 in Q3 2025.
- A 5-year average of $835050.0 and a median of $181500.0 in 2021 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2021 — Other financing activities tumbled 99.94% — and 2024, when it surged 1446.22%.
- Tracing KROS's Other financing activities over 5 years: stood at $245000.0 in 2021, then sank by 58.37% to $102000.0 in 2022, then surged by 688.24% to $804000.0 in 2023, then surged by 204.1% to $2.4 million in 2024, then plunged by 95.3% to $115000.0 in 2025.
- The last three Other financing activities figures came in at $115000.0 (Q4 2025), $2000.0 (Q3 2025), and $17000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 115,000.00 |
| Dec 31, 2025 | 115,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 2.45 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | 2.97 Mn |
| Mar 31, 2024 | 5.72 Mn |
| Mar 31, 2024 | 5.72 Mn |
| Dec 31, 2023 | 804,000.00 |
| Dec 31, 2023 | 804,000.00 |
| Sep 30, 2023 | 311,000.00 |
| Sep 30, 2023 | 311,000.00 |